|1.||Parola, Maurizio: 5 articles (01/2014 - 01/2009)|
|2.||Novo, Erica: 3 articles (01/2014 - 01/2010)|
|3.||Paternostro, Claudia: 3 articles (01/2014 - 01/2010)|
|4.||Thompson, Nicola D: 2 articles (08/2015 - 03/2013)|
|5.||Godine, Deborah: 2 articles (08/2015 - 03/2013)|
|6.||Ray, Susan: 2 articles (08/2015 - 03/2013)|
|7.||Edwards, Jonathan R: 2 articles (08/2015 - 03/2013)|
|8.||Kainer, Marion: 2 articles (08/2015 - 03/2013)|
|9.||Bamberg, Wendy: 2 articles (08/2015 - 03/2013)|
|10.||Dumyati, Ghinwa: 2 articles (08/2015 - 03/2013)|
|1.||Liver Diseases (Liver Disease)
12/01/2012 - "Recent studies have shown a pathological role of angiogenesis in the progression of chronic liver diseases (CLDs). "
01/21/2010 - "Experimental and clinical studies have unequivocally reported that hepatic angiogenesis, irrespective of aetiology, occurs in conditions of chronic liver diseases (CLDs) characterized by perpetuation of cell injury and death, inflammatory response and progressive fibrogenesis. "
03/01/2009 - "The aim of this study was to analyze the pathological characteristics of HCC and nontumoral liver in patients with MS as the only risk factor for liver disease in comparison with those that developed in the course of other CLDs in order to provide further insight into the physiopathology of HCC associated with MS. HCC patients with features of MS as the only risk factor for liver diseases (MS group, n = 31) were compared to HCC patients with overt causes of CLD (CLD group, n = 81) or without causes of CLD (cryptogenic group, n = 16) who underwent surgical resection during the same period of time. "
12/01/2007 - "During a study period of 7 years, all patients with chronic liver diseases (CLDs) were evaluated for the presence of AILDs on the basis of clinical, biochemical, imaging, serological, and histological characteristics. "
08/01/2015 - "Considering the size of the population affected by Chronic Liver Diseases (CLDs) and the severity and chronic nature of the symptoms, there is an emerging need to evaluate the quality of life of patients using a standard protocol. "
04/01/2015 - "The age-gender-adjusted rate ratio (95% confidence interval; P value) in 2008-2011 was 0.78 (0.76-0.80; P < 0.001) for CLDs and cirrhosis mortality, 0.76 (0.75-0.78; P < 0.005) for HCC mortality, and 0.86 (0.85-0.88; P < 0.005) for HCC incidence using 2000-2003 as the reference period (rate ratio = 1.0). "
04/01/2015 - "Male gender and elder age were associated with a significantly increased risk of CLDs and cirrhosis and HCC. "
04/01/2015 - "There were 42,526 CLDs and cirrhosis deaths, 47,392 HCC deaths, and 74,832 incident HCC cases occurred in 140,814,448 person-years from 2000 to 2011. "
03/27/2015 - "This review mainly focuses to give a clear view on the relevant features that communicate angiogenesis with progression of fibrosis in CLDs towards the-end point of cirrhosis that may be translated into future therapies. "
03/27/2015 - "Because anti-angiogenic therapy has been found to be efficient in the prevention of fibrosis in experimental models of CLDs, it is suggested that blocking angiogenesis could be a promising therapeutic option in patients with advanced fibrosis. "
|3.||Wounds and Injuries (Trauma)
|4.||Hepatocellular Carcinoma (Hepatoma)
01/01/2009 - "Fibrogenesis progression has a major worldwide clinical impact due to the high number of patients affected by CLDs, increasing mortality rate, incidence of hepatocellular carcinoma and shortage of organ donors for liver transplantation. "
12/01/2013 - "We performed a systematic review of the literature, through February 2013, for studies that followed up patients with CLDs prospectively for at least 6 months and reported the association between baseline LSM and subsequent development of decompensated cirrhosis or hepatocellular carcinoma (HCC), as well as mortality. "
03/01/2012 - "Liver macronodules, ranging from benign to low-grade or high-grade dysplastic nodules (LGDNs/HGDNs) and hepatocellular carcinoma (HCC), may develop during chronic liver diseases (CLDs). "
06/01/2006 - "In the present study, by using Huh7 cells, derived from human hepatoma and competent for VLDL secretion, we found that ApoB is highly concentrated around CLDs to make "ApoB-crescents." ApoB-crescents were seen in <10% of Huh7 cells under normal conditions, but the ratio increased to nearly 50% after 12 h of proteasomal inhibition by N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal. "
04/01/2015 - "Age-gender-adjusted incidence and mortality rates of hepatocellular carcinoma (HCC) and chronic liver diseases (CLDs) and cirrhosis of adults ages 30-69 years were compared before and after launching the program using Poisson's regression models. "
|5.||Lymphoproliferative Disorders (Lymphoproliferative Disorder)
07/01/1999 - "In this study, we investigated the expression and function of CXCR3 on normal and malignant B cells from 65 patients with chronic lymphoproliferative disorders (CLDs). "
08/01/2000 - "We have investigated whether the quantitative flow cytometry is an useful tool to better characterize B-cell chronic lymphoproliferative disorders (CLDs). "
01/01/2000 - "Sometimes, however, it fails to discriminate among several chronic lymphoproliferative disorders (CLDs). "
07/01/1991 - "The authors evaluated the expression and diagnostic utility of CD22 and CD11C in specimens from 26 normal subjects, 29 patients, with various nonlymphoproliferative disorders (NLPDs), and 75 patients with different types of chronic lymphoproliferative disorders (CLDs) using two-color flow cytometric analysis of peripheral blood lymphocytes. "
07/01/1991 - "These markers were expressed in greater than 10% of the lymphocytes of 46% (32/69) of the patients with B-cell CLDs: B-cell chronic-lymphocytic leukemia, 9/41; B-cell non-Hodgkin's lymphoma, 8/14; HCL, 11/11; B-cell lymphoproliferative disorder (NOS), 1/2; and B-cell prolymphocytic leukemia, 1/1. None (0/6) of the lymphocytes of patients with T-cell CLDs expressed greater than 10% CD22-positive (CD22+) or CD11c-positive (CD11c+) cells. "
|1.||Aspartate Aminotransferases (Aspartate Transaminase)
|3.||Apolipoproteins B (ApoB)
|4.||Biological Markers (Surrogate Marker)
|6.||Proteins (Proteins, Gene)
|7.||TIE-2 Receptor (Receptor, TIE 2)
|8.||CD40 Ligand (CD40L)
|9.||Interleukin-17 (Interleukin 27)
|10.||Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)
|2.||Transplantation (Transplant Recipients)